Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps

In September 2019, The Lancet published details of two large Phase III double-blind placebo-controlled studies (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) confirming the clinical efficacy of the biologic dupilumab in simultaneously blocking both IL-4/IL-13 signalling in chronic rhinosinusitis with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kariyawasam, Harsha H, James, Louisa K, Gane, Simon B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217316/
https://www.ncbi.nlm.nih.gov/pubmed/32440101
http://dx.doi.org/10.2147/DDDT.S243053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217316/
https://www.ncbi.nlm.nih.gov/pubmed/32440101
http://dx.doi.org/10.2147/DDDT.S243053

Ejemplares similares